AI-assisted, human-published

03/26/2025 /Funding Events

Epicrispr Biotechnologies Secures $68 Million for FSHD Therapy Development

Epicrispr Biotechnologies raises significant funding to advance the development of EPI-321, a revolutionary therapy for FSHD, led by Ally Bridge Group and SOLVE FSHD.

 

AI-assisted, human-published

Latest headlines







join us

Join us for funding and investment opportunities.

Stay connected!

If you have a serious, bonafide inquiry into the VentureCapital.com or PrivateEquity.com domain names, please contact us here

©2023 VentureCapital.com